|
The First Results of the Use of Liprimar for Correction of Hyperlipidaemia in the Secondary Coronary Prevention |
|
G. Chapidze,
S. Kapanadze, N.
Dolidze, N. Salukvadze , |
|
To evaluate lipid lowering effect of short term treatment with liprimar (Atorvastatin, Pfizer) 59 post interventional (angiography, PTCA, CABG) patients were examined. Eligible patients were counseled to follow a standard lipid lowering diet (NCEP step 1 Diet). Twenty-nine patients were randomly assigned to receive Liprimar 10mg/daily. Intended follow-up was a month. As one of the first goal of treatment in the secondary coronary prevention is the reduction of LDL-C, the main criteria to enroll patients in the present trial was baseline levels of LDL-C >100mg/dl. According to our investigation atorvastatin reduced total-C, LDL-C, TG, beta and pre-beta lipoproteins and atherogenic ratio (Total-C-HDL-C/HDL-C)by 21%, 26%, 14%, 20%and 23% respectively. HDL-C levels increased by only 3%. By Liprimar the reduction of LDL-C less than 100mg/dl (target level) was achieved in 62% cases. In a diet group there were no significant changes in lipid profile. During the experienced period none of the serious adverse reactions of statins were noticed. In conclusion, the results of this trial indicate that in patients who had undergone angiography , PTCA and CABG short term treatment with 10mg/d of liprimar is beneficial for the correction of hyperlipidaemia (particularly in relation to LDL-C levels). Consequently,
as other HMF-coA reductase
inhibitors liprimar
may be
considered as one
of the first
line agents
in the secondary coronary prevention. |
| Literature: |
|
1.
National Cholesterol Education Program.
Second report of the expert panel on detection, evaluation and
treatment of high blood cholesterol in adults. // Circulation 1994; 89;
1329-1445. |
| Contents |